Subscribe to RSS
Download PDF
DOI: 10.1055/s-0042-113460
Effects of Streptozotocin-Induced Diabetes on Proliferation and Differentiation Abilities of Mesenchymal Stem Cells Derived from Subcutaneous and Visceral Adipose Tissues
Publication History
received 29 February 2016
first decision 08 July 2016
accepted 26 July 2016
Publication Date:
22 September 2016 (online)
Abstract
Introduction: Accumulated evidence indicates that there are intrinsic differences between adipose tissue-derived stem cells (ASCs) obtained from different body fat depots. Here, we compared the proliferation and multipotency of subcutaneous ASCs (SC-ASCs) and epididymal ASCs (ED-ASCs) before and after induction of diabetes by streptozotocin.
Methods: The adipogenic and osteogenic abilities of rat SC-ASCs and ED-ASCs were evaluated using Oil Red O and Alizarin Red staining, respectively. The expression of adipocyte (PPAR-γ, LPL) and osteoblast (ALP, SPP1) specific mRNAs was evaluated by quantitative real-time PCR. MTT test was used for determination of cell proliferation capacity.
Results: The proliferation of SC-ASCs was higher than ED-ASCs, both before and after diabetes induction (P<0.05). Diabetes increased the proliferative capability of SC-ASCs (P<0.05) but not ED-ASCs. Before diabetes, both adipogenic and osteogenic differentiation of SC-ASCs were higher than ED-ASCs (P<0.05). After diabetes, both SC-ASCs and ED-ASCs were able to differentiate into adipocyte and osteoblast, but the levels of differentiation were higher in SC-ASCs than in ED-ASCs (P<0.05). Diabetes decreased the expression of PPAR-γ and LPL, but increased the SPP1 and ALP expression in both SC-ASCs and ED-ASCs.
Conclusion: Our data suggested that diabetes increases the proliferation of ASCs but decreases their adipogenic differentiation. Also, SC-ASCs have higher proliferation and differentiation abilities than ED-ASCs in normal and diabetic conditions so can be more preferable for cell therapy.
-
References
- 1 Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084
- 2 Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-316
- 3 You DH, Nam MJ. Effects of human epidermal growth factor gene-transfected mesenchymal stem cells on fibroblast migration and proliferation. Cell Prolif 2013; 46: 408-415
- 4 Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int 2012; 2012: 461718
- 5 Ikegame Y, Yamashita K, Hayashi S et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011; 13: 675-685
- 6 Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem cells (Dayton, Ohio) 2006; 24: 1294-1301
- 7 Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 2013; 34: 1-11
- 8 Lin G, Wang G, Liu G et al. Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cell Dev 2009; 18: 1399-1406
- 9 Volarevic V, Arsenijevic N, Lukic ML et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem cells 2011; 29: 5-10
- 10 Trivedi HL, Vanikar AV, Thakker U et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplan Proc 2008; 40: 1135-1139
- 11 Thakkar UG, Trivedi HL, Vanikar AV et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 2015; 17: 940-947
- 12 Joe AW, Yi L, Even Y et al. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem cells 2009; 27: 2563-2570
- 13 Requicha JF, Viegas CA, Albuquerque CM et al. Effect of anatomical origin and cell passage number on the stemness and osteogenic differentiation potential of canine adipose-derived stem cells. Stem Cell Rev 2012; 8: 1211-1222
- 14 Toyoda M, Matsubara Y, Lin K et al. Characterization and comparison of adipose tissue-derived cells from human subcutaneous and omental adipose tissues. Cell Biochem Func 2009; 27: 440-447
- 15 Ghorbani A, Varedi M, Hadjzadeh MA et al. Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes 2010; 118: 442-428
- 16 Ghorbani A, Omrani GR, Hadjzadeh MA et al. Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme. Horm Metab Res 2013; 45: 221-225
- 17 Ghorbani A, Jalali SA, Varedi M. Isolation of adipose tissue mesenchymal stem cells without tissue destruction: a non-enzymatic method. Tissue Cell 2014; 46: 54-58
- 18 Feizpour A, Boskabady MH, Ghorbani A. Adipose-derived stromal cell therapy affects lung inflammation and tracheal responsiveness in guinea pig model of COPD. Plos One 2014; 9: e108974
- 19 Yu G, Floyd ZE, Wu X et al. Adipogenic differentiation of adipose-derived stem cells. Methods Mol Biol 2011; 702: 193-200
- 20 Aguena M, Dalto Fanganiello R, Tissiani LAL et al. Optimization of parameters for a more efficient use of adipose-derived stem cells in regenerative medicine therapies. Stem cells Int 2012; 2012: 7
- 21 Ghorbani A, Rajaei Z, Zendehbad SB. Effects of fenugreek seeds on adipogenesis and lipolysis in normal and diabetic rats. Pakistan J Biol Sci 2014; 17: 523-528
- 22 Hsu LW, Goto S, Nakano T et al. The effect of exogenous histone H1 on rat adipose-derived stem cell proliferation, migration, and osteogenic differentiation in vitro. J Cell Physiol 2012; 227: 3417-3425
- 23 Alford AI, Reddy AB, Goldstein SA et al. Two molecular weight species of thrombospondin-2 are present in bone and differentially modulated in fractured and nonfractured tibiae in a murine model of bone healing. Calcified tissue Int 2012; 90: 420-428
- 24 Pevsner-Fischer M, Morad V, Cohen-Sfady M et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-1432
- 25 Baglioni S, Cantini G, Poli G et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. Plos One 2012; 7: e36569
- 26 Ferrer-Lorente R, Bejar MT, Badimon L. Notch signaling pathway activation in normal and hyperglycemic rats differs in the stem cells of visceral and subcutaneous adipose tissue. Stem Cells Dev 2014; 23: 3034-3048
- 27 Stolzing A, Sellers D, Llewelyn O et al. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2012; 191: 453-465
- 28 Ferrer-Lorente R, Bejar MT, Tous M et al. Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function. Diabetologia 2014; 57: 246-256
- 29 Jumabay M, Moon JH, Yeerna H et al. Effect of diabetes mellitus on adipocyte-derived stem cells in rat. J Cell Physiol 2015; 230: 2821-2828
- 30 Tchkonia T, Giorgadze N, Pirtskhalava T et al. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes 2006; 55: 2571-2578
- 31 Minteer DM, Young MT, Lin YC et al. Analysis of type II diabetes mellitus adipose-derived stem cells for tissue engineering applications. J. Tissue Eng 2015; 6: 1-12
- 32 Oliva-Olivera W, Leiva Gea A, Lhamyani S et al. Differences in the osteogenic differentiation capacity of omental adipose-derived stem cells in obese patients with and without metabolic syndrome. Endocrinology 2015; 156: 4492-4501
- 33 Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Physical Ther 2008; 88: 1254-1264
- 34 Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin N Am 2015; 99: 87-106
- 35 Meah F, Juneja R. Insulin tactics in type 2 diabetes. Med Clin N Am 2015; 99: 157-186
- 36 Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed) 2009; 339: b4731
- 37 Lind M, Svensson A-M, Kosiborod M et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972-1982
- 38 Godfrey KJ, Mathew B, Bulman JC et al. Stem cell-based treatments for type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabetic Med 2012; 29: 14-23
- 39 Chhabra P, Brayman KL. Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cell Translat Med 2013; 2: 328-336
- 40 Fadini GP, Albiero M, Vigili de Kreutzenberg S et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013; 36: 943-949
- 41 Cianfarani F, Toietta G, Di Rocco G et al. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 2013; 21: 545-553
- 42 Ghorbani A, Naderi-Meshkin H. The endocrine regulation of stem cells: physiological importance and pharmacological potentials for cell-based therapy. Curr Stem Cell Res Ther 2016; 11: 19-34